Arcus Biosciences Inc (NYSE: RCUS) open the trading on Thursday, with great promise as it jumped 4.16% to $9.51, before settling in for the price of $9.13 at the close. Taking a more long-term approach, RCUS posted a 52-week range of $6.50-$18.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 172.99% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -10.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -44.65%. This publicly-traded company’s shares outstanding now amounts to $105.90 million, simultaneously with a float of $63.89 million. The organization now has a market capitalization sitting at $1.01 billion. At the time of writing, stock’s 50-day Moving Average stood at $8.33, while the 200-day Moving Average is $13.29.
Arcus Biosciences Inc (RCUS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arcus Biosciences Inc’s current insider ownership accounts for 39.66%, in contrast to 62.43% institutional ownership. According to the most recent insider trade that took place on Feb 27 ’25, this organization’s Director bought 20,000 shares at the rate of 10.06, making the entire transaction reach 201,200 in total value, affecting insider ownership by 28,400. Preceding that transaction, on Feb 27 ’25, Company’s Chief Executive Officer bought 19,800 for 10.18, making the whole transaction’s value amount to 201,465. This particular insider is now the holder of 2,554,160 in total.
Arcus Biosciences Inc (RCUS) Earnings and Revenue Records
Arcus Biosciences Inc’s EPS decrease for this current 12-month fiscal period is -44.65% and is forecasted to reach -4.40 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -6.52% through the next 5 years, which can be compared against the -10.20% growth it accomplished over the previous five years trading on the market.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arcus Biosciences Inc (RCUS). It’s Quick Ratio in the last reported quarter now stands at 5.37. The Stock has managed to achieve an average true range (ATR) of 0.53. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.14.
In the same vein, RCUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.19, a figure that is expected to reach -1.12 in the next quarter, and analysts are predicting that it will be -4.40 at the market close of one year from today.
Technical Analysis of Arcus Biosciences Inc (RCUS)
[Arcus Biosciences Inc, RCUS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 83.65% While, its Average True Range was 0.51.
Raw Stochastic average of Arcus Biosciences Inc (RCUS) in the period of the previous 100 days is set at 33.02%, which indicates a major fall in contrast to 92.59% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 39.10% that was lower than 67.68% volatility it exhibited in the past 100-days period.
